2025-525076-29-00
Recruiting
Phase 1
Crossover study to investigate the safety and tolerability as well as the blood levels after three single doses of Tacrolimus, of which 2 are administered via the cheek mucosa and 1 dose via the mouth (oral).
Nucleus Medical GmbH1 site in 1 country6 target enrollmentStarted: March 1, 2026Last updated:
Overview
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Nucleus Medical GmbH
- Enrollment
- 6
- Locations
- 1
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Elke Hortskotte
Scientific
Nucleus Medical GmbH
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Study is designed to assess the safety and tolerability of ceralasertib at increasing doses in combination with other anti-cancer treatment in patients with advanced tumours2023-505006-41-00AstraZeneca AB100
Recruiting
Phase 1
A Phase 1 Study to Investigate the Safety and Tolerability of the Study Drug GB-0895 in Mild to Moderate Asthma Patients or Single Dose in Chronic Obstructive Pulmonary Disease (COPD)2023-507611-35-00Generate Biomedicines Inc.70
Suspended
Phase 1
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors2023-505322-34-00Beigene Ltd.45
Suspended
Phase 1
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab, in Patients With Advanced or Metastatic Solid Tumors2023-503996-38-00Beigene Ltd.60
Recruiting
Phase 1
A study investigating the safety, tolerability, metabolism, and elimination of INE963, a new compound in the treatment of malaria.2024-516911-26-00Novartis Pharma AG94